Recombinant Human Fumarylacetoacetase/FAH Protein (His Tag)

Catalog Number: PKSH032463



Note: Centrifuge before opening to ensure complete recovery of vial contents. Description **Species** Human Mol Mass 47.4 kDa Accession P16930 **Bio-activity** Not validated for activity **Properties** > 95 % as determined by reducing SDS-PAGE. Purity < 1.0 EU per µg of the protein as determined by the LAL method. Endotoxin Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80 Storage °C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at $< -20^{\circ}$ C for 3 months. This product is provided as lyophilized powder which is shipped with ice packs. Shipping Lyophilized from a 0.2 µm filtered solution of 20mM Tris-HCl, 150mM NaCl, pH 8.5. Formulation Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual. Please refer to the printed manual for detailed information. Reconstitution D

Data			
	kDa	MKR	
	120		
	120 90 60	ence	
	40		
	Elabscien 30	Science	
		elektron	
	20 Flabsc	-	
	14		

> 95 % as determined by reducing SDS-PAGE.

Background

Fumarylacetoacetase belongs to the FAH family. Fumarylacetoacetase is primary expressed in liver and kidney. It exists as a homodimer and catalyzes the hydrolysis of 4-fumarylacetoacetate into fumarate and acetoacetate. Defects in Fumarylacetoacetase cause tyrosinemia type 1, which is congenital metabolism defect characterized by elevated levels of tyrosine in the blood and urine, and hepatorenal manifestations. Typical features include renal tubular injury, self-mutilation, hepatic necrosis, episodic weakness, and seizures.

For Research Use Only